At a glance
- Retatrutide is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 213 publications mentioning it, including 10 randomized controlled trials and 11 animal-only studies.
- ClinicalTrials.gov lists 34 registered studies testing it (11 active).
- FDA's adverse event system (FAERS) holds 44 reports mentioning it; 33 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Single or multiple nutritional hormone receptor modulators for chronic kidney disease.
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
- Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.
- Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.
- Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.
- GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.
- Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile.
- Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 34
- Active
- 11
- With posted results
- 2
Conditions studied
Show 24 more studies
All 34 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 44
- Serious
- 33
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
In the news
Latest headlines and official notices that mention this substance, in their original language. Third-party content, not medical advice.
Change history
No changes since monitoring began on October 30, 2026.